<DOC>
	<DOC>NCT02688023</DOC>
	<brief_summary>Colorectal cancer is an aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with resectable colorectal cancer.</brief_summary>
	<brief_title>Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer</brief_title>
	<detailed_description>This is a single arm, phase 2 study of neoadjuvant triplet chemotherapy regimen of oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with resectable colorectal cancer.Fifty patients will be enrolled in this trial. The primary objective of this study is to determine the 3-year disease-free survival of the patients.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>histologically verified colorectal cancer clinical stage T4N02M0„ÄÅcT13N2M0 or M1(liver metastases only) age: 1870 years ECOG 02 adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease) no prior cancer and/or chemotherapy signed informed consent patients with a history of prior malignancy pregnant or lactating patients known or suspected brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>5-fluorouracil</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>chemotherapy</keyword>
</DOC>